8-K: QuidelOrtho Reports Mixed Q2 Results Amidst Cost-Saving Initiatives

QuidelOrtho's second quarter results show a revenue decrease due to lower COVID-19 sales, but recurring revenue grew, and the company is implementing cost-saving measures.

Summary

• QuidelOrtho reported a total revenue of $637 million for the second quarter of 2024, a decrease from $665 million in the same period last year, primarily due to reduced COVID-19 revenue.
• The company experienced a GAAP diluted loss per share of ($2.20), compared to a loss of ($0.80) in the prior year, and a GAAP operating loss of ($118) million, compared to ($27) million in the prior year.
• Adjusted diluted loss per share was ($0.07), compared to an adjusted diluted EPS of $0.26 in the prior year, and adjusted EBITDA was $90 million, down from $113 million.
• Recurring revenue, excluding COVID-19 and U.S. Donor Screening revenue, grew by 3% as reported and 5% in constant currency for the quarter, and 6% as reported and 7% in constant currency year-to-date.
• The company is implementing $100 million in annualized cost-savings initiatives expected to benefit the second half of 2024 and the first half of 2025.
• A significant review of assets, operations, and opportunities for savings was undertaken, which will inform the company's long-range plan.
• The company incurred $31 million in integration-related charges and a $57 million asset impairment charge related to long-term assets held for sale.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to the reported losses and revenue decline, although the cost-saving initiatives and recurring revenue growth provide some positive aspects. The significant asset impairment charge and integration costs are concerning.

Positives

• Recurring revenue showed growth of 3% as reported and 5% in constant currency for the quarter, indicating strength in core business areas.
• Year-to-date recurring revenue grew 6% as reported and 7% in constant currency, demonstrating positive momentum.
• The company is implementing $100 million in annualized cost-savings initiatives, which are expected to improve profitability in the near term.
• A comprehensive business review was conducted to identify areas for improvement and growth, which will inform the company's long-range plan.
• The company is refocusing R&D investments on core growth areas, which should lead to better returns in the future.

Negatives

• Total revenue decreased to $637 million from $665 million in the prior year, primarily due to lower COVID-19 revenue.
• The company reported a GAAP diluted loss per share of ($2.20), a significant decrease compared to the loss of ($0.80) in the prior year.
• Adjusted diluted loss per share was ($0.07), compared to an adjusted diluted EPS of $0.26 in the prior year.
• GAAP operating loss was ($118) million, compared to ($27) million in the prior year.
• Adjusted EBITDA decreased to $90 million from $113 million in the prior year.
• The company incurred $31 million in integration-related charges and a $57 million asset impairment charge.

Risks

• The company is facing challenges related to lower COVID-19 revenue, which is impacting overall financial performance.
• Integration-related costs and asset impairment charges are negatively affecting profitability.
• Foreign currency translation negatively impacted second quarter results by 100 basis points.
• The company's financial results are subject to macroeconomic, geopolitical, market, business, competitive and regulatory factors.
• There are risks associated with integrating the business combination of Quidel Corporation and Ortho Clinical Diagnostics Holdings plc.

Future Outlook

The company's strategic priorities include operating the business to provide exceptional customer satisfaction, improving the cost structure, focusing on high-growth areas, and strengthening its position as a leading in-vitro diagnostic company. The $100 million in annualized cost savings are expected to benefit the second half of 2024 and the first half of 2025.

Management Comments

• During the second quarter we performed in line with our expectations across all segments and geographies while concurrently undertaking a significant review of our assets, operations, and opportunities for further company-wide savings, said Brian J. Blaser, President and Chief Executive Officer, QuidelOrtho.
• The findings of our internal review will serve as the foundation for our long-range plan to drive growth and improve margins, as well as focusing our R&D efforts and investments on the areas where we see the greatest opportunity and return.
• During the second quarter, I had the opportunity to engage with many of our customers, employees, and investors, reinforcing my belief in QuidelOrthos long-term opportunity, said Brian J. Blaser.

Industry Context

The in-vitro diagnostics industry is experiencing shifts in demand, particularly with the decline in COVID-19 testing. QuidelOrtho's focus on recurring revenue and cost-saving initiatives reflects a broader trend in the industry to adapt to changing market conditions and improve profitability.

Comparison to Industry Standards

• QuidelOrtho's revenue decline due to reduced COVID-19 testing is consistent with trends seen in other diagnostic companies such as Abbott and Roche, which have also reported lower COVID-19 related revenues.
• The company's focus on cost-saving initiatives and R&D refocusing is similar to strategies employed by other companies in the sector to improve margins and drive growth in core business areas.
• The reported GAAP loss per share and operating loss are worse than some competitors, indicating potential challenges in operational efficiency and integration.
• The growth in recurring revenue, excluding COVID-19 impacts, is a positive sign and aligns with the industry's focus on sustainable revenue streams.

Stakeholder Impact

• Shareholders are negatively impacted by the reported losses and decreased profitability.
• Employees may be affected by the cost-saving initiatives and restructuring efforts.
• Customers should expect continued service and product quality, with a focus on customer satisfaction.
• Suppliers may be impacted by changes in the company's operations and cost structure.

Next Steps

• The company will continue to implement its cost-saving initiatives.
• QuidelOrtho will focus on aligning operating expenses with revenue expectations.
• The company will continue to focus R&D efforts on key priorities.
• The company will hold a conference call to discuss the financial results.

Key Dates

Keywords

QuidelOrtho, financial results, recurring revenue, cost savings, in-vitro diagnostics, COVID-19, EBITDA, loss per share, asset impairment, integration